Dulaglutide
Also known as: dulaglutide, LY2189265, NN9535, Trulicity
Source Dulaglutide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Dulaglutide is a once‑weekly, injectable glucagon‑like peptide‑1 (GLP‑1) receptor agonist approved for the treatment of type 2 diabetes. By enhancing glucose‑dependent insulin secretion and reducing appetite, it lowers blood glucose and promotes modest weight loss. Clinical trials have shown that dulaglutide also reduces the risk of major cardiovascular events in people with diabetes and established atherosclerotic disease, making it a key option for patients needing both glycaemic and cardiovascular protection.
Mechanism of Action
Dulaglutide mimics the endogenous hormone GLP‑1 and binds to the GLP‑1 receptor on pancreatic β‑cells, amplifying insulin secretion only when glucose is elevated. It simultaneously suppresses glucagon release from α‑cells, slows gastric emptying, and acts on central pathways to decrease food intake. These actions together improve post‑prandial and fasting glucose, lower HbA1c, and contribute to weight reduction. The prolonged half‑life of dulaglutide, achieved by fusion to an Fc fragment, enables sustained receptor activation with weekly dosing.
What the Research Shows
Evidence for dulaglutide comes from large cardiovascular outcome trials and class reviews. The REWIND trial, a double‑blind, placebo‑controlled study, evaluated dulaglutide’s impact on major adverse cardiovascular events in adults with type 2 diabetes and established atherosclerotic disease, providing key data that supported its cardiovascular benefit. A recent SURPASS‑CVOT trial directly compared tirzepatide with dulaglutide, showing tirzepatide was non‑inferior to dulaglutide for the composite endpoint of cardiovascular death, myocardial infarction, or stroke, confirming dulaglutide’s robust efficacy as an active comparator. A 2021 state‑of‑the‑art review of GLP‑1 receptor agonists highlighted dulaglutide’s weekly dosing, consistent HbA1c reduction, weight loss, low hypoglycaemia risk, and its role as a preferred injectable therapy before insulin. Together, these sources establish dulaglutide’s efficacy for glycaemic control, weight management, and cardiovascular risk reduction, while noting comparable safety to other agents in its class.
Reported Benefits
Clinical data demonstrate that dulaglutide lowers HbA1c and promotes modest weight loss in people with type 2 diabetes, with a low intrinsic risk of hypoglycaemia when used alone. The REWIND trial provided evidence of reduced major cardiovascular events, supporting its use in patients with existing atherosclerotic disease. Its once‑weekly administration improves adherence compared with more frequent injectable agents, and the long‑acting formulation maintains steady receptor activation.
Limitations of the Evidence
Evidence for dulaglutide’s cardiovascular benefit derives primarily from the REWIND population, which had established atherosclerotic disease; benefits in lower‑risk groups are less certain. Direct head‑to‑head comparisons with other GLP‑1 agonists are limited, and long‑term safety beyond trial durations remains under observation. Gastrointestinal side effects can limit tolerability, and the SURPASS‑CVOT trial only demonstrated non‑inferiority to tirzepatide without showing superiority.
Safety Considerations
The most common adverse effects are gastrointestinal, including nausea, vomiting, and diarrhoea, which are generally mild to moderate and tend to diminish with dose titration. Dulaglutide carries a low risk of hypoglycaemia unless combined with insulin or sulfonylureas. Contra‑indications include a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Caution is advised in patients with a history of pancreatitis, severe renal impairment, or gallbladder disease, and regular monitoring is recommended during therapy.
How It Is Administered
Dulaglutide is supplied as a prefilled pen for subcutaneous injection once weekly. The injection is administered in the abdomen, thigh, or upper arm, rotating sites to minimise local reactions. Dosing is typically started at a low level and may be increased based on glycaemic response and tolerability, following a healthcare professional’s guidance.
Routes of Administration
Goals & Uses
- Weight managementBody CompositionModerate
- Blood pressure reductionCardiovascularModerate
- Cardiovascular risk reductionCardiovascularHigh
- Glycemic controlDiabetesHigh
- Renal protectionRenalModerate
- Weight reductionMetabolicModerate
- Glycemic control in type 2 diabetesMetabolicHigh
Contraindications
- Personal or family history of medullary thyroid carcinomaOncologicHigh
- Diabetic ketoacidosisMetabolicHigh
- Hypersensitivity to dulaglutide or excipientsImmunologicalHigh
- Hypersensitivity to dulaglutide or any excipientImmunologicModerate
- Medullary thyroid carcinomaOncologyHigh
- Type 1 diabetes mellitusEndocrineHigh
- Multiple endocrine neoplasia type 2 (MEN 2)OncologyHigh
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Genetic/EndocrineHigh
Adverse Effects
- Hypoglycemia (when combined with insulin or sulfonylureas)MetabolicUncommon
- PancreatitisGastrointestinalRareInflammation of the pancreas
- HypoglycemiaMetabolicUncommonAbnormally low blood glucose
- Injection site reactionsLocalUncommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalCommonForceful expulsion of stomach contents
- DiarrheaGastrointestinalCommonLoose or frequent stools
Drug Interactions
- Insulin and insulin secretagogues (e.g., sulfonylureas)High
- InsulinHighMay increase risk of low blood sugar
- WarfarinModerate
- Oral medications with narrow therapeutic indexModerate
- SulfonylureasHighMay increase risk of low blood sugar
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patients (under 18 years)AgeRelative
- Pediatric patients (<18 years)AgeRelative
- Severe renal impairment (eGFR <15 mL/min/1.73m²)RenalRelative
- Diabetic ketoacidosisMetabolicAbsolute
- Type 1 diabetes mellitusDiabetesAbsolute
- Severe gastrointestinal diseaseGastrointestinalRelative
- Patients with prior pancreatitisPancreaticRelative
Regulatory Status
- European UnionApprovedApproved: type 2 diabetes mellitusApproved under the same dosing regimen as in the United States.
- United StatesApprovedApproved: type 2 diabetes mellitusApproved for once‑weekly subcutaneous administration.
- United KingdomApprovedApproved: type 2 diabetes mellitusApproved by the MHRA for weekly subcutaneous injection.
Approved in the United States (2014), European Union (2015) and United Kingdom (2015).
Evidence & Sources
- Journal ArticleModerateNicholls SJ, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateNauck MA, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleModerateGerstein HC, et al.2019-01-01T00:00:00.000000Z
- Journal ArticleModerateCoskun T, et al.2018-01-01T00:00:00.000000Z
- Journal ArticleHighKristensen SL, et al.2019-01-01T00:00:00.000000Z
- Journal ArticleModerateFrance NL, Syed YY2024-01-01T00:00:00.000000Z
Frequently Asked Questions
How quickly does dulaglutide lower blood sugar?
Dulaglutide begins to improve glycaemic control within the first few weeks of therapy, with maximal HbA1c reductions generally observed after several months of consistent weekly dosing.
Can dulaglutide be used with other diabetes medicines?
Yes, dulaglutide can be combined with oral agents such as metformin, SGLT‑2 inhibitors, or DPP‑4 inhibitors, and with basal insulin. When used with insulin or sulfonylureas, dose adjustments may be needed to avoid hypoglycaemia.
What should I do if I experience nausea?
Mild nausea is common early in treatment. It often improves as the body adapts. If severe, discuss with a clinician who may suggest a slower dose escalation or temporary anti‑nausea measures.
Is dulaglutide safe for people with kidney disease?
Dulaglutide does not require dose adjustment for mild to moderate renal impairment, but caution and monitoring are advised in severe kidney disease, as data are limited.
Why is dulaglutide given once a week instead of daily?
The molecule is fused to an Fc fragment that extends its half‑life, allowing sustained GLP‑1 receptor activation with a single weekly injection, which improves convenience and adherence compared with daily GLP‑1 agonists.
What is Dulaglutide?
Dulaglutide is a once‑weekly, injectable glucagon‑like peptide‑1 (GLP‑1) receptor agonist approved for the treatment of type 2 diabetes. By enhancing glucose‑dependent insulin secretion and reducing appetite, it lowers blood glucose and promotes modest weight loss. Clinical trials have shown that dulaglutide also reduces the risk of major cardiovascular events in people with diabetes and established atherosclerotic disease, making it a key option for patients needing both glycaemic and cardiovascular protection.
What is Dulaglutide used for?
Dulaglutide is educationally associated with: Weight management, Blood pressure reduction, Cardiovascular risk reduction, Glycemic control, Renal protection, Weight reduction, Glycemic control in type 2 diabetes. Educational only — not medical advice.
How is Dulaglutide administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Dulaglutide?
Reported adverse effects include: Hypoglycemia (when combined with insulin or sulfonylureas), Pancreatitis, Hypoglycemia, Injection site reactions, Nausea, Vomiting, Diarrhea. This list is not exhaustive — consult a qualified clinician.
Who should avoid Dulaglutide?
Recorded contraindications: Personal or family history of medullary thyroid carcinoma, Diabetic ketoacidosis, Hypersensitivity to dulaglutide or excipients, Hypersensitivity to dulaglutide or any excipient, Medullary thyroid carcinoma, Type 1 diabetes mellitus, Multiple endocrine neoplasia type 2 (MEN 2), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Consult a qualified clinician before use.